The world of IVF 'add-ons' has long been shrouded in mystery, with many patients left wondering whether these optional extras are worth the hefty price tag. A significant new study published in The Lancet Obstetrics, Gynaecology, & Women's Health sheds light on this pressing issue, questioning the effectiveness and value of numerous therapies offered alongside IVF treatments.
According to the Human Fertilisation and Embryology Authority (HFEA), a staggering 73% of fertility patients in the UK have opted for an additional test, treatment, or emerging technology during their IVF journey. These add-ons can include procedures such as PGT-A (preimplantation genetic testing for aneuploidy) and endometrial scratching, as well as more unconventional methods like platelet-rich plasma infusion into the uterus or acupuncture.
The study, which comprised a systematic review and meta-analysis of 85 trials, scrutinised the efficacy and safety of ten common IVF add-ons. Researchers from the University of Oxford, the University of Melbourne, and the UMC University of Amsterdam highlighted the prevalence of low-quality studies in the field, making it difficult for patients and clinicians to make informed decisions.
The economic implications are substantial: while a single IVF cycle can cost several thousand pounds, add-ons can inflate the total expense significantly. Some treatments can cost hundreds or even thousands of pounds per cycle, adding thousands to a patient's overall bill. This financial burden can be crushing for individuals or couples undergoing multiple cycles.
The lack of clear evidence raises serious questions about consumer protection and the ethical responsibilities of fertility clinics in guiding patients through complex treatment decisions. As businesses in the sector re-evaluate their services, this study serves as a timely reminder to prioritise evidence-based practices over unsubstantiated claims.